Tirzepatide FDA Approval for Weight Loss: What Changed

In November 2023, the FDA approved tirzepatide under the brand name Zepbound for chronic weight management — marking a watershed moment in obesity treatment. With clinical trial data showing up to 22.5% average body weight loss, tirzepatide became the most effective FDA-approved weight loss medication ever. Here is the complete story of how this dual-agonist drug achieved approval and what it means for patients.

What Makes Tirzepatide Unique

Tirzepatide, developed by Eli Lilly and Company, is the first FDA-approved medication to target two incretin hormone receptors simultaneously. While semaglutide and other GLP-1 receptor agonists target only the GLP-1 receptor, tirzepatide activates both:

• GLP-1 (glucagon-like peptide-1) receptor: Reduces appetite, slows gastric emptying, and improves insulin secretion — the same target as semaglutide
• GIP (glucose-dependent insulinotropic polypeptide) receptor: Enhances insulin sensitivity, influences fat metabolism, and may contribute additional appetite-suppressing effects through mechanisms still being researched

This dual mechanism is often referred to as a "twincretin" approach. The synergistic effect of activating both receptors produces weight loss that exceeds what either pathway alone can achieve.

Tirzepatide Approval Timeline

The SURMOUNT Clinical Trial Program

Tirzepatide's weight loss approval was built on the SURMOUNT trial program, which enrolled thousands of participants across multiple studies. These trials established tirzepatide as the gold standard for pharmaceutical weight loss.

SURMOUNT-1: The Landmark Trial

SURMOUNT-1 was the pivotal trial that drove Zepbound's approval. It enrolled 2,539 adults with obesity or overweight with at least one weight-related comorbidity, but without type 2 diabetes.

To put these numbers in perspective: at the 15 mg dose, the average participant starting at 231 lbs lost approximately 52 lbs. More than half of participants lost over 20% of their body weight — a threshold previously achievable only through bariatric surgery.

SURMOUNT-2: Diabetes and Obesity

Tested tirzepatide in 938 adults with both type 2 diabetes and obesity. Average weight loss was 14.7% at the 15 mg dose over 72 weeks, with significant A1C improvements. As with semaglutide, weight loss in people with diabetes tends to be somewhat lower due to metabolic factors.

SURMOUNT-3: After Intensive Lifestyle Intervention

Examined whether tirzepatide could help maintain weight loss achieved through an initial 12-week intensive lifestyle intervention (low-calorie diet). Participants who received tirzepatide after their initial diet-based weight loss continued to lose additional weight, achieving a total loss of 26.6% from their original weight.

SURMOUNT-4: Maintenance and Withdrawal

Addressed the critical question: what happens when you stop tirzepatide? After 36 weeks on tirzepatide, participants were randomized to continue the medication or switch to placebo. Those continuing tirzepatide lost an additional 5.5% of body weight, while those on placebo regained 14.0%. This confirmed the need for ongoing treatment.

What the Zepbound Approval Changed

The approval of tirzepatide for weight loss had ripple effects throughout medicine:

Raised the Bar for Weight Loss Medications

With average weight loss exceeding 20% at the highest dose, tirzepatide reset expectations for what pharmaceutical weight loss can achieve. Previous medications like phentermine, orlistat, and even semaglutide produced significantly less weight loss. Tirzepatide brought pharmaceutical results closer to bariatric surgery outcomes.

Validated the Multi-Receptor Approach

Tirzepatide's success proved that targeting multiple hormone pathways simultaneously can produce superior results. This has accelerated research into triple-agonist medications (like retatrutide, which targets GLP-1, GIP, and glucagon receptors) and combination therapies.

Increased Insurance Scrutiny and Access Debates

With another highly effective but expensive medication on the market, insurance companies, employers, and policymakers faced renewed pressure to address coverage for obesity treatment. The cost — approximately $1,000-1,200 per month without insurance — has fueled ongoing debates about pharmaceutical pricing and access equity.

Expanded the Compounding Market

Tirzepatide's placement on the FDA Drug Shortage List enabled compounding pharmacies to produce compounded versions at significantly lower cost, expanding access but also raising quality and safety questions that regulators continue to address.

Safety Profile

The SURMOUNT trials established tirzepatide's safety profile for weight management. The most common side effects are gastrointestinal:

• Nausea: Reported in 24-33% of participants (usually transient during dose escalation)
• Diarrhea: 17-23% of participants
• Vomiting: 9-13% of participants
• Constipation: 11-17% of participants
• Injection site reactions: Mild and infrequent

Discontinuation rates due to adverse events were 4.3-7.1% across doses, which is relatively low for this drug class. The medication carries the same black box warning as other GLP-1 drugs regarding thyroid C-cell tumors observed in rodent studies (clinical relevance in humans is uncertain).

For a deeper dive into how tirzepatide works, visit our how it works page. To explore treatment options including tirzepatide, see our treatments page.